U.S. Personal Products Stock News

Campbell's (CPB) has had a rough stretch this year, with the stock sliding about 32% year to date even as revenue and net income are still inching higher, creating an interesting value setup. See our latest analysis for Campbell's. That slide reflects a market that is rethinking how much it is willing to pay for steady, slower growth, with the 1 year total shareholder return down 28.04% even as fundamentals improve. This suggests sentiment has weakened more than the underlying business. If...

Hagerty (HGTY) just reported that its Broad Arrow subsidiary handled over $624 million in collector car transactions in 2025, with 97% year over year growth. That sharp acceleration is getting investors’ attention. See our latest analysis for Hagerty. The strong Broad Arrow update lands while Hagerty’s share price sits at $13.13, and its year to date share price return of 32.89% signals building momentum, backed by a robust 3 year total shareholder return of 65.16%. If this kind of growth...

The board of ABM Industries Incorporated ( NYSE:ABM ) has announced that it will be paying its dividend of $0.29 on the...

In recent days, Garrett Motion has attracted a wave of upbeat analyst coverage, including new ratings and refreshed research highlighting its leading role in turbochargers and emerging zero-emission technologies. This flurry of attention underscores how Garrett’s blend of internal combustion engine exposure and growing electrified offerings is reshaping how investors view its earnings resilience. We’ll now examine how this fresh analyst enthusiasm, especially around Garrett’s zero-emission...

Eastman Chemical (EMN) has quietly lagged the broader market this year, but its recent bounce over the past month has some investors revisiting the stock as a potential value opportunity. See our latest analysis for Eastman Chemical. That recent 30 day share price return of 6.77% looks more like a short term relief move than a trend change, given the year to date share price return is still down 28.20% and the five year total shareholder return sits firmly in negative territory. If Eastman’s...

Earlier in December 2025, International Flavors & Fragrances saw a senior executive buy shares while the company increased investment in taste, scent and bio‑innovation capabilities focused on natural and sustainable ingredients. This combination of insider buying and higher spending on AI‑enabled, bio‑based formulations underscores internal conviction that consumer and regulatory trends favor IFF’s innovation-focused portfolio. We’ll now examine how this insider purchase, set against rising...

Hamilton Insurance Group recently appointed industry veteran Dwayne Hunt as Senior Vice President and Head of Property Insurance at Hamilton Re, succeeding Gavin Davis, while also presenting at the UBS Global Specialty Insurance/Reinsurance Virtual Conference on 16 December 2025. The move underscores Hamilton’s emphasis on internal succession and experienced underwriting leadership in its property portfolio, a cornerstone of its specialty (re)insurance business. We’ll now examine how Hunt’s...

Pebblebrook Hotel Trust (PEB) has been quietly grinding higher this month, and that slow climb makes the stock worth a closer look. Recent returns hint at shifting sentiment around its hotel portfolio. See our latest analysis for Pebblebrook Hotel Trust. Zooming out, the 30 day share price return of 3.97% barely dents a negative year to date share price return of 13.26%, while the one year total shareholder return of 14.75% in the red shows that momentum is still rebuilding rather than fully...

Recent performance and what is driving interest First Hawaiian (FHB) has quietly put together a steady run, with the stock up about 7 % over the past month and 4 % in the past 3 months, drawing fresh attention from income focused bank investors. See our latest analysis for First Hawaiian. Zooming out, the stock’s roughly mid single digit year to date share price gain, alongside a 1 year total shareholder return of about 7 %, suggests momentum is quietly rebuilding as investors reassess risks...

The board of Scholastic Corporation ( NASDAQ:SCHL ) has announced that it will pay a dividend on the 16th of March...

With its stock down 9.0% over the past three months, it is easy to disregard Meritage Homes (NYSE:MTH). However, the...

Franklin Resources, Inc. ( NYSE:BEN ) has announced that it will be increasing its periodic dividend on the 9th of...

Some Cencora, Inc. ( NYSE:COR ) shareholders may be a little concerned to see that the Senior VP, Lazarus Krikorian...

Halozyme Therapeutics recently received FDA approval for RYBREVANT FASPRO, co-formulated with its ENHANZE platform for advanced EGFR-mutated non-small cell lung cancer, and earlier this month secured a preliminary patent injunction in Germany against a rival subcutaneous product. Together with the addition of commercialization veteran Jim Lang to its board, these developments reinforce Halozyme’s positioning at the center of subcutaneous biologic drug delivery and IP protection. We’ll now...

In Q3 2025, Bilibili reported a net profit after earlier losses as stronger user engagement and higher advertising revenue lifted performance, while China’s Politburo shifted toward a moderately loose monetary policy to support domestic demand and technology investment for 2026. This combination of an earnings turnaround and a policy stance favoring digital consumption highlights how platform engagement and macro support may reinforce Bilibili’s role in China’s online entertainment...

Bread Financial Holdings (BFH) just saw Fitch assign a B minus rating to its new perpetual preferred stock, building on an earlier issuer upgrade to BB with a stable outlook that underscores improving credit quality. See our latest analysis for Bread Financial Holdings. The latest Fitch actions and a run of earnings beats seem to be feeding into sentiment, with the share price now at $78.0 and a strong 30 day share price return of 20.56 percent helping extend a 26.14 percent 1 year total...

In December 2025, Biohaven Ltd. reported at the ESMO Immuno-Oncology Congress that its Trop2-directed antibody drug conjugate BHV-1510, combined with Regeneron’s anti-PD-1 cemiplimab, showed encouraging safety and efficacy signals across several solid tumors, including non-small cell lung, endometrial, urothelial, and triple negative breast cancers. The early-stage data, including a confirmed objective response rate above half in evaluable patients and durable participation beyond six...

Analysts have just lifted earnings forecasts for ZTO Express (Cayman) (NYSE:ZTO) for this year and 2026, citing stronger parcel volumes, healthier revenue in core express delivery, and solid operational execution. See our latest analysis for ZTO Express (Cayman). Those upgraded earnings forecasts arrive after a solid run in the stock, with the 1 month share price return of 10.67 percent and year to date share price gain of 11.77 percent suggesting positive momentum. At the same time, the 3...

In mid-December 2025, Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer to apply its T-cell receptor discovery platform to rheumatoid arthritis and to license its extensive TCR–antigen binding dataset for Pfizer’s AI and machine learning-driven drug discovery efforts. The deals underscore the commercial potential of Adaptive’s immune repertoire data, with the rheumatoid arthritis collaboration alone carrying up to about US$890 million in possible milestones...

In recent days, multiple research firms including Truist Securities, Goldman Sachs, Citigroup, Barclays and Stifel reiterated positive views on Parker-Hannifin, signaling broad analyst confidence in the company’s operational and earnings outlook. This cluster of reaffirmed positive ratings and upgraded opinions effectively acts as a sentiment catalyst, spotlighting Parker-Hannifin as a preferred name among large-cap industrial and aerospace suppliers. Next, we’ll examine how this wave of...

Aptiv (NYSE:APTV) just expanded its automation ambitions by teaming up with Vecna Robotics to co develop autonomous mobile robots that aim to provide safer, more efficient material handling and a fresh avenue for long term growth. See our latest analysis for Aptiv. The Vecna Robotics tie up lands after a solid year to date share price return of roughly 30 percent, even though longer term total shareholder returns over three and five years remain negative. This suggests momentum is rebuilding...

Spyre Therapeutics (SYRE) just caught Wall Street’s eye, with firms like Mizuho and Citi initiating upbeat coverage that centers on its antibody pipeline for autoimmune and inflammatory diseases and upcoming clinical milestones. See our latest analysis for Spyre Therapeutics. Those upbeat notes are landing after a powerful run, with a 30 day share price return of roughly 38 percent and a 90 day share price return of around 118 percent. Meanwhile, the three year total shareholder return above...

Cipher Mining (CIFR) is suddenly on a lot more watchlists after locking in a multi billion dollar AI data center lease with Amazon Web Services, plus an expanded, Google backed Fluidstack hosting deal. See our latest analysis for Cipher Mining. Those AI infrastructure deals are arriving on the back of serious momentum, with a 30 day share price return of 14.56 percent and a year to date share price return of 235.61 percent. The three year total shareholder return of 2,901.85 percent shows how...

Relay Therapeutics, Inc. recently presented a subset analysis of interim data from its first-in-human ReDiscover trial, highlighting zovegalisib’s efficacy and tolerability in heavily pretreated HR+/HER2- advanced breast cancer patients at the 2025 San Antonio Breast Cancer Symposium. The data showed consistent progression-free survival and response rates across challenging subgroups, such as prior SERD exposure and ESR1-mutated tumors, reinforcing interest in this allosteric PI3Ka...